Cite
MLA Citation
Qing Zhou et al.. “Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.” Lancet oncology, vol. 23, no. 2, 2022, pp. 209–219. http://access.bl.uk/ark:/81055/vdc_100150529983.0x000013